{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:35:25Z","timestamp":1793936125539,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PPP Allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen (SGF) under projectnumber LSHM18055-SGF"},{"name":"the Blaauboer Fund via the AMC Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic lymphocytic leukemia (CLL) cells upregulate Bcl-2 proteins within the lymph node (LN) microenvironment. Signaling via B-cell receptor, Toll-like receptors and CD40 collectively reduce sensitivity to the BCL-2 inhibitor venetoclax. Time-limited treatment with venetoclax plus the BTK-inhibitor ibrutinib results in deep remissions, but how this combination affects LN-related signaling is not yet completely clear. Therefore, samples obtained from the HOVON141\/VISION phase 2 clinical trial were used to analyze this. Two cycles of lead-in ibrutinib monotherapy resulted in decreased protein expression of Bcl-2 proteins in circulating CLL cells. Strikingly, at this timepoint CD40-induced venetoclax resistance was strongly attenuated, as was expression of CD40. Since CD40 signaling occurs within the CLL LN, we tested various LN-related signals that could affect CD40 signaling. While BCR stimulation had only a minor effect, TLR9 stimulation via CpG led to significantly increased CD40 expression and importantly, reverted the effects of ibrutinib treatment on venetoclax sensitivity by inducing overall protein translation. Together, these findings identify a novel effect of ibrutinib: interruption of TLR9-induced CD40 upregulation and translation of pro-survival proteins. This mechanism may potentially further inhibit priming of CLL cells in the LN microenvironment for venetoclax resistance.<\/jats:p>","DOI":"10.1038\/s41375-023-01898-w","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T14:04:25Z","timestamp":1682517865000},"page":"1268-1276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation"],"prefix":"10.1038","volume":"37","author":[{"given":"Karoline","family":"Kielbassa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco V.","family":"Haselager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danique J. C.","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca F.","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Svanberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-6640","authenticated-orcid":false,"given":"Eric","family":"Eldering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"1898_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","volume":"27","author":"Y Herishanu","year":"2013","unstructured":"Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin N Am. 2013;27:173\u2013206.","journal-title":"Hematol Oncol Clin N Am"},{"key":"1898_CR2","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","volume":"28","author":"M Haselager","year":"2021","unstructured":"Haselager M, Thijssen R, West C, Young L, Van Kampen R, Willmore E, et al. Regulation of Bcl-XL by non-canonical NF-kappaB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021;28:1658\u201368.","journal-title":"Cell Death Differ"},{"key":"1898_CR3","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","volume":"122","author":"MF Pascutti","year":"2013","unstructured":"Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R, et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood. 2013;122:3010\u20139.","journal-title":"Blood."},{"key":"1898_CR4","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1038\/onc.2010.248","volume":"29","author":"JM Tromp","year":"2010","unstructured":"Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering. Oncogene. 2010;29:5071\u201382.","journal-title":"Oncogene."},{"key":"1898_CR5","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","volume":"113","author":"M Vogler","year":"2009","unstructured":"Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:4403\u201313.","journal-title":"Blood."},{"key":"1898_CR6","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","volume":"112","author":"DY Hallaert","year":"2008","unstructured":"Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood. 2008;112:5141\u20139.","journal-title":"Blood."},{"key":"1898_CR7","first-page":"e302","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100:e302\u20136.","journal-title":"Haematologica."},{"key":"1898_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.celrep.2013.07.011","volume":"4","author":"A Os","year":"2013","unstructured":"Os A, Burgler S, Ribes AP, Funderud A, Wang D, Thompson KM, et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep. 2013;4:566\u201377.","journal-title":"Cell Rep"},{"key":"1898_CR9","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215\u201324.","journal-title":"Blood."},{"key":"1898_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.","journal-title":"Mol Cancer"},{"key":"1898_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28:649\u201357.","journal-title":"Leukemia."},{"key":"1898_CR12","doi-asserted-by":"publisher","first-page":"e89904","DOI":"10.1172\/jci.insight.89904","volume":"2","author":"JA Burger","year":"2017","unstructured":"Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017;2:e89904.","journal-title":"JCI Insight"},{"key":"1898_CR13","doi-asserted-by":"publisher","first-page":"592205","DOI":"10.3389\/fonc.2020.592205","volume":"10","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kater AP, Eldering E. Proliferative signals in chronic lymphocytic leukemia; what are we missing? Front Oncol. 2020;10:592205.","journal-title":"Front Oncol"},{"key":"1898_CR14","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2018-03-837864","volume":"131","author":"F Forconi","year":"2018","unstructured":"Forconi F. Five years of ibrutinib in CLL. Blood. 2018;131:2280\u20131.","journal-title":"Blood."},{"key":"1898_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","volume":"15","author":"JA Burger","year":"2018","unstructured":"Burger JA, O\u2019Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15:510\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"1898_CR16","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","volume":"5","author":"AP Kater","year":"2021","unstructured":"Kater AP, Slinger E, Cretenet G, Martens AW, Balasubramanian S, Leverson JD, et al. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv. 2021;5:5410\u20134.","journal-title":"Blood Adv"},{"key":"1898_CR17","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095\u2013103.","journal-title":"N Engl J Med"},{"key":"1898_CR18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood.2020008608","volume":"137","author":"CU Niemann","year":"2021","unstructured":"Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, et al. Venetoclax and ibrutinib for patients with relapsed\/refractory chronic lymphocytic leukemia. Blood. 2021;137:1117\u201320.","journal-title":"Blood."},{"key":"1898_CR19","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"1898_CR20","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139:3278\u201389.","journal-title":"Blood."},{"key":"1898_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","volume":"23","author":"AP Kater","year":"2022","unstructured":"Kater AP, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23:818\u201328.","journal-title":"Lancet Oncol"},{"key":"1898_CR22","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:EVIDoa2200006.","journal-title":"NEJM Evid."},{"key":"1898_CR23","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2019004326","volume":"136","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, et al. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136:2918\u201326.","journal-title":"Blood."},{"key":"1898_CR24","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929\u201336.","journal-title":"Leukemia."},{"key":"1898_CR25","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287\u201396.","journal-title":"Blood."},{"key":"1898_CR26","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/leu.2017.129","volume":"31","author":"E Slinger","year":"2017","unstructured":"Slinger E, Thijssen R, Kater AP, Eldering E. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017;31:2601\u20137.","journal-title":"Leukemia."},{"key":"1898_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02329-y","volume":"8","author":"DA Landau","year":"2017","unstructured":"Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8:2185.","journal-title":"Nat Commun"},{"key":"1898_CR28","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood."},{"key":"1898_CR29","doi-asserted-by":"publisher","first-page":"e039168","DOI":"10.1136\/bmjopen-2020-039168","volume":"10","author":"MD Levin","year":"2020","unstructured":"Levin MD, Kater AP, Mattsson M, Kersting S, Ranti J, Thi Tuyet Tran H, et al. Protocol description of the HOVON 141\/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance >\/=30 mL\/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations. BMJ Open. 2020;10:e039168.","journal-title":"BMJ Open"},{"key":"1898_CR30","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.V85.7.1903.bloodjournal8571903","volume":"85","author":"M Urashima","year":"1995","unstructured":"Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 1995;85:1903\u201312.","journal-title":"Blood."},{"key":"1898_CR31","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI119822","volume":"100","author":"JL Schultze","year":"1997","unstructured":"Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Investig. 1997;100:2757\u201365.","journal-title":"J Clin Investig"},{"key":"1898_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","volume":"17","author":"C Calissano","year":"2011","unstructured":"Calissano C, Damle RN, Marsilio S, Yan XJ, Yancopoulos S, Hayes G, et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells. Mol Med. 2011;17:1374\u201382.","journal-title":"Mol Med"},{"key":"1898_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2015-07-660969","volume":"127","author":"A Yeomans","year":"2016","unstructured":"Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Hidalgo MS, et al. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood. 2016;127:449\u201357.","journal-title":"Blood."},{"key":"1898_CR34","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1182\/blood-2006-05-021683","volume":"109","author":"LA Smit","year":"2007","unstructured":"Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP, et al. Differential Noxa\/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007;109:1660\u20138.","journal-title":"Blood."},{"key":"1898_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/biof.62","volume":"35","author":"A Chatzigeorgiou","year":"2009","unstructured":"Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E. CD40\/CD40L signaling and its implication in health and disease. Biofactors. 2009;35:474\u201383.","journal-title":"Biofactors."},{"key":"1898_CR36","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/onc.2016.515","volume":"36","author":"MHA van Attekum","year":"2017","unstructured":"van Attekum MHA, Terpstra S, Slinger E, von Lindern M, Moerland PD, Jongejan A, et al. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. Oncogene. 2017;36:3651\u201360.","journal-title":"Oncogene."},{"key":"1898_CR37","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31:2075\u201384.","journal-title":"Leukemia."},{"key":"1898_CR38","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1182\/blood-2014-04-567198","volume":"124","author":"S Krysov","year":"2014","unstructured":"Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, et al. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood. 2014;124:3101\u20139.","journal-title":"Blood."},{"key":"1898_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36853-8","volume":"9","author":"C Schleiss","year":"2019","unstructured":"Schleiss C, Ilias W, Tahar O, Guler Y, Miguet L, Mayeur-Rousse C, et al. BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Sci Rep. 2019;9:701.","journal-title":"Sci Rep"},{"key":"1898_CR40","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4049\/jimmunol.1403189","volume":"195","author":"PK Mongini","year":"2015","unstructured":"Mongini PK, Gupta R, Boyle E, Nieto J, Lee H, Stein J, et al. TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells. J Immunol. 2015;195:901\u201323.","journal-title":"J Immunol"},{"key":"1898_CR41","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563\u201374.","journal-title":"Blood."},{"key":"1898_CR42","doi-asserted-by":"crossref","unstructured":"Delgado R, Kielbassa K, Ter Burg J, Klein C, Trumpfheller C, de Heer K, et al. Co-stimulatory versus cell death aspects of agonistic CD40 monoclonal antibody selicrelumab in chronic lymphocytic leukemia. Cancers. 2021;13:3084.","DOI":"10.3390\/cancers13123084"},{"key":"1898_CR43","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SE Herman","year":"2014","unstructured":"Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286\u201395.","journal-title":"Blood."},{"key":"1898_CR44","doi-asserted-by":"crossref","unstructured":"Chen Z, Simon-Molas H, Cretenet G, Valle-Argos B, Smith LD, Forconi F, et al. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood. 2022;140:630\u201343.","DOI":"10.1182\/blood.2021013990"},{"key":"1898_CR45","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1182\/blood.2020005627","volume":"137","author":"S Sharma","year":"2021","unstructured":"Sharma S, Pavlasova GM, Seda V, Cerna KA, Vojackova E, Filip D, et al. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021;137:2481\u201394.","journal-title":"Blood."},{"key":"1898_CR46","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/0008-5472.CAN-18-0781","volume":"79","author":"EL Dadashian","year":"2019","unstructured":"Dadashian EL, McAuley EM, Liu D, Shaffer AL 3rd, Young RM, Iyer JR, et al. TLR signaling is activated in lymph node-resident CLL cells and is only partially inhibited by ibrutinib. Cancer Res. 2019;79:360\u201371.","journal-title":"Cancer Res"},{"key":"1898_CR47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","volume":"560","author":"JD Phelan","year":"2018","unstructured":"Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560:387\u201391.","journal-title":"Nature."},{"key":"1898_CR48","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood.2020005964","volume":"137","author":"E Kennedy","year":"2021","unstructured":"Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137:3064\u201378.","journal-title":"Blood."},{"key":"1898_CR49","doi-asserted-by":"crossref","unstructured":"Riley JS, Quarato G, Cloix C, Lopez J, O\u2019Prey J, Pearson M, et al. Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. EMBO J. 2018;37:e99238.","DOI":"10.15252\/embj.201899238"},{"key":"1898_CR50","doi-asserted-by":"publisher","first-page":"e49799","DOI":"10.15252\/embr.201949799","volume":"21","author":"JS Riley","year":"2020","unstructured":"Riley JS, Tait SW, Mitochondrial DNA. in inflammation and immunity. EMBO Rep. 2020;21:e49799.","journal-title":"EMBO Rep"},{"key":"1898_CR51","doi-asserted-by":"crossref","unstructured":"Martines C, Chakraborty S, Vujovikj M, Gobessi S, Vaisitti T, Deaglio S, et al. Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo. Blood. 2022;140:2335\u201347.","DOI":"10.1182\/blood.2022016272"},{"key":"1898_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.leu.2404417","volume":"21","author":"PG Longo","year":"2007","unstructured":"Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21:110\u201320.","journal-title":"Leukemia."},{"key":"1898_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cyto.2013.03.023","volume":"62","author":"G Ghalamfarsa","year":"2013","unstructured":"Ghalamfarsa G, Jadidi-Niaragh F, Hojjat-Farsangi M, Asgarian-Omran H, Yousefi M, Tahmasebi F, et al. Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. Cytokine 2013;62:439\u201345.","journal-title":"Cytokine"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01898-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01898-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T20:30:32Z","timestamp":1686083432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01898-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1898"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01898-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}